Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies
Abstract
SARS-CoV-2 has emerged as a world public health threat. Herein, we report that the clinical approved auranofin could perfectly inhibit the activity of 3-chymotrypsin-like cysteine protease (Mpro or 3CLpro) of SARS-CoV-2. Gold cluster could significantly inhibit 3CLpro of SARS-COV-2. Phenyl isothiocyanate and Vitamin K3 could well suppress the activity of 3CLpro. For Mpro inhibition, IC50 of auranofin, Vitamin K3, phenyl isothiocyanate, gold cluster are about 0.51M, 7.96M, 10.13M, 1.61M, respectively. These compounds may be with potentials for treatment SARS-CoV-2 virus replication. Especially for FDA approved auranofin, it is an anti-inflammation drug in clinic, thus it may with strong potential to inhibit virus replication and suppress the inflammation damage in COVID-19 patients. Gold cluster is with better safety index and well anti-inflammation in vitro/vivo, therefore it is with potential to inhibit virus replication and suppress the inflammation damage caused by COVID-19 virus. As Au(I) ion is active metabolism specie derived from gold compounds or gold clusters in vivo, further computational studies revealed Au ion could tightly bind thiol group of Cys145 residue of 3CLpro thus inhibit enzyme activity. Also, phenyl isothiocyanate and Vitamin K3 may interact with thiol group of Cys145 via Michael addition reaction, molecular dynamic (MD) theory studied are applied to confirmed these small molecules are stable in the pocket and inhibit Mpro activity.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen
Maria Kuzikov, Elisa Costanzi, … Andrea Zaliani·ACS Pharmacology & Translational SciencePeer-reviewed·Mar 11, 2021
- A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors
Enrico Glaab, Ganesh babu Manoharan, Daniel Abankwa·Journal of Chemical Information and ModelingPeer-reviewed·Aug 4, 2021
- Inhibition of SARS-CoV-2 3CLpro in vitro by chemically modified tyrosinase from Agaricus bisporus
D. Aguilera, J. M. Palomo·bioRxiv·Mar 13, 2023
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
W. Vuong, M. B. Khan, … M. J. Lemieux·bioRxiv·May 3, 2020
- Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
M. M. Ghahremanpour, J. Tirado-Rives, … W. L. Jorgensen·bioRxiv·Aug 28, 2020